Summarized by Masters of Longevity from Longevity Technology.
A roundup-style article on a large mouse-based longevity screening and the company's plans to translate hits into drug and pet therapies.
Key Takeaways
- Longevica screened 1,033 small-molecule compounds across more than 16,000 mice over natural lifespans during a four-year study.
- The company reports 60+ life-extending compounds and two candidate mechanisms to build new classes of drugs.
- Longevica formed a 12-member Scientific Advisory Board and named Prasun Mishra CEO to push toward preclinical and clinical development.
